---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-193428"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2023-07-25T23:59:59+00:00"
generated_at: "2026-06-13T03:21:36.531081+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BMF-219 induces 2 complete responses in 5 AML patients with menin mutations in Phase I trial

## Summary
- 2 of 5 relapsed/refractory AML patients with menin-dependent mutations achieved CRs at Dose Level 4 (500mg or 125mg QD).
- CRs observed within first two 28-day cycles; both patients continue on BMF-219 treatment.
- No dose-limiting toxicities or QTc prolongation reported; generally well tolerated.
- Dose Level 5 enrollment commenced to explore optimal biological dose.
- Biomea plans to present additional data at an upcoming medical conference.

## SEC filing metadata
- accession: 0001193125-23-193428
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2023-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312523193428/0001193125-23-193428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312523193428/d434383d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-193428
- JSON: https://secwatch.observer/filing/0001193125-23-193428.json
- Plain text: https://secwatch.observer/filing/0001193125-23-193428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.